EMA Authorised: Heplisav B (hepatitis B surface antigen) — Dynavax GmbH

View source ↗

Summary

The European Medicines Agency authorised Heplisav B, a hepatitis B vaccine based on hepatitis B surface antigen, for use in the European Union. The marketing au…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HEPLISAV-B (hepatitis B vaccine, adjuvanted)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B. MAH: Dynavax GmbH. Decision date: 17/11/2025